Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients

Abstract

Aims: The population pharmacokinetics of 131I-mAbF19, a radiolabelled murine monoclonal antibody against fibroblast activation protein and a potential antitumour stroma agent, were investigated during two phase I studies in cancer patients. Methods: 131I-mAbF19 serum concentration-time data were obtained in 16 patients from two studies involving imaging and dosimetry in colorectal carcinoma and soft tissue sarcoma. Doses of 0.2, 1 and 2 mg antibody were administered as 60 min intravenous infusions. The data were analysed by nonlinear mixed effect modelling. Results: The data were described by a two-compartment model. Population mean values were 109 ml h-1 for total serum clearance, 3.1 l for..